Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 22.33M P/E - EPS this Y 15.10% Ern Qtrly Grth -
Income -35.97M Forward P/E -1.03 EPS next Y 19.50% 50D Avg Chg 4.00%
Sales 1.85M PEG - EPS past 5Y - 200D Avg Chg -47.00%
Dividend N/A Price/Book 0.43 EPS next 5Y - 52W High Chg -73.00%
Recommedations 2.30 Quick Ratio 2.73 Shares Outstanding 2.96M 52W Low Chg 46.00%
Insider Own 9.23% ROA -63.09% Shares Float 2.71M Beta 1.39
Inst Own 16.33% ROE -118.06% Shares Shorted/Prior 24.21K/15.39K Price 0.38
Gross Margin - Profit Margin - Avg. Volume 250,659 Target Price 19.67
Oper. Margin -1,106.49% Earnings Date Nov 7 Volume 89,938 Change -2.49%
About Oncternal Therapeutics, Inc.

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.

Oncternal Therapeutics, Inc. News
10/22/24 Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
09/12/24 Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives
08/11/24 Oncternal Therapeutics Second Quarter 2024 Earnings: Beats Expectations
08/08/24 Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results
08/01/24 Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results
07/15/24 Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
07/11/24 Oncternal Therapeutics to Present in JonesTrading Healthcare Summit
05/30/24 Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
05/09/24 Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
05/02/24 Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results
05/01/24 Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
04/18/24 Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
03/15/24 Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
03/10/24 Oncternal Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
03/07/24 Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
02/29/24 Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results
02/06/24 Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
01/08/24 Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
01/04/24 Oncternal Therapeutics Announces Reverse Stock Split
12/26/23 Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma
ONCT Chatroom

User Image rag2riches Posted - 1 hour ago

$ONCT pumpers are here. Come on let's see which one of you has the strongest discord chat. Marketcap and float is puny so if you chats had any weight you should be able to move this and cause a short squeeze

User Image LuckyCs Posted - 2 hours ago

$ONCT It can go! 🧐

User Image Bobby_J_Bomb Posted - 2 hours ago

$ONCT how cool would it be to fill this pattern with a mid to late December Xmas gift announcement? They have $4 cash/share, only 3 mm shares and 10% inside ownership!!

User Image LuckyCs Posted - 3 hours ago

$ONCT 💪

User Image Bobby_J_Bomb Posted - 4 hours ago

$ONCT Filed last week that they are getting rid of the rest of their employees and keeping 4 part time. $2.4 mm cost associated with this, essentially leaving $12.1 mm, not including any other costs in the quarter, which they state are minimal. This would be around $4/share, not including any sales of assets or IP. Pretty decent R/R here for a 100%+ gain in a couple months. https://investor.oncternal.com/static-files/79f8d542-4566-4995-9d66-ed2f884dbdd1

User Image Bobby_J_Bomb Posted - 2 days ago

$XBI $SPRB $VTGN $VSTM $ONCT https://finance.yahoo.com/news/healthcare-executives-expect-more-ipos-141704801.html

User Image Bobby_J_Bomb Posted - 2 days ago

$ONCT How long does this review take? In the meantime, how about distributing cash while we wait to see if we can flip any of the clinical assets or technology!

User Image rag2riches Posted - 1 week ago

$ONCT who caught that dip? You would be up close to 30%. Much more room to go

User Image rag2riches Posted - 1 week ago

$ONCT just bought 4.6k shares to average down. Fuck it. Pumpers might be coming back soon to pick up these cheapies

User Image HoHoHoHum Posted - 1 week ago

$ONCT testing the lows today!

User Image pablin Posted - 1 week ago

$ONCT Gentlemen, Do you think we are going to know the outcome before the end of the year???

User Image zoomlik Posted - 1 week ago

$ONCT Best deal here is a RM (valuing compay at say $10M) and then a CVR for asset sale to split proceeds 50:50 by acquiring company and CVR holders

User Image SDBiotechInvestor Posted - 2 weeks ago

$ONCT Hearing BioTechValues going to rebuy the shares he dumped on y'all today tomorrow morning. This guy is just as bad as his master Donald Trump

User Image joe77w Posted - 2 weeks ago

$ONCT cash on hand 4.5 USD per share, net equity 3 USD, not accounting for 4 compounds available for potential monetization plus NASDAQ listing worth Upto 10 mln USD for reverse merger. 1/3 months and we could get positive news imo, worst case scenario liquidation around 1.5/2 USD per share Do your due diligence before investing your Money this Is not a financial advice

User Image STR33 Posted - 2 weeks ago

$ONCT tax loss evidence...

User Image pablin Posted - 2 weeks ago

$ONCT I hate this management The are truly liers

User Image SDBiotechInvestor Posted - 2 weeks ago

$ONCT -

User Image SDBiotechInvestor Posted - 2 weeks ago

$ONCT 10Q. No commentary of timing or any progress in terms of asset sales. Probably a long road here.

User Image BiotechValues Posted - 2 weeks ago

$ONCT So $14.6M cash and burn is now probably ~$3M in q4. Trading around liquidation value. Free call option on the asset sales. Continue to reiterate that in 10q: "On September 12, 2024, the Company announced that its Board decided to discontinue the Company’s clinical trials evaluating ONCT-534 and ONCT-808 as well as all other product development activities, and to begin exploring strategic alternatives to maximize the value of the Company’s assets for its stockholders. The Company commenced a reduction-in-force beginning in September 2024, and is continuing to assess further cost reduction measures as its operational and strategic direction evolves. As part of the review of strategic alternatives, the Company may consider options such as asset sales or out-licensing opportunities for existing programs and merger, reverse merger or other business combination opportunities."

User Image joe77w Posted - 2 weeks ago

$ONCT if assets (4 Compounds) sold for total meager 10 mln USD and a reverse merger engeneered stock Could go to 8 USD because 10 mln USD would be nearly 3.35 USD per share, add net cash position around 5 mln (estimated) or 1.67 USD per share plus NASDAQ listing worth around 10 mln USD 3.35 USD again...8.85 USD if Company able to monetize assets for 10 mln if Company cash net of liabilities 4.5 mln usd and if reverse merger deal done... 8.37 would be worth around 25 mln USD with Os around 3 mln Without reverse merger and in case of liquidation and dissolution assuming costs and a 3 Years lenghty process, my estimate would be lower, around 4 usd Just pure speculation, do your DD before investing your Money, this Is not a financial advice! Worst scenario imo liquidation around 4 mln USD or 1.42 USD per share

User Image BiotechValues Posted - 2 weeks ago

$ONCT should be getting the 10q any day now. Will see if they say anything in regards to the asset sale process that has been ongoing for ~ 2 months now. Reminder, that CFO in early Oct said this will be a fast/efficient process, with potential outcomes over a couple/few months

User Image Brendalikesthestock Posted - 2 weeks ago

$ONCT bullish

User Image BiotechValues Posted - 10/31/24

$ONCT they seem pretty happy with last week's surprise news:

User Image BiotechValues Posted - 10/31/24

$ONCT obviously the big recent development was the news that they were starting to see efficacy with ONCT-534 in the N=6 "twice daily dosing" cohorts. Maybe adds value/interest to the asset sale process for that asset https://investor.oncternal.com/news-releases/news-release-details/oncternal-therapeutics-announces-updated-safety-and-efficacy

User Image BiotechValues Posted - 10/31/24

$ONCT back to the $1.40s level, same area it was at before it popped to $2.30s last week. I'm a buyer here. Should get q3 update next week and hopefully some commentary on the status of the asset sale process. Thesis: https://x.com/BioValues/status/1847371756077797563

User Image bbonct Posted - 10/29/24

$ONCT so, any value in having a patent? Even after you discontinue the therapy?

User Image PatentGrants Posted - 10/29/24

$ONCT Oncternal Therapeutics has been granted US patent number 12,128,026 titled "Selective androgen receptor degrader ligands and methods of use thereof (for the treatment of prostate cancer)". https://ppubs.uspto.gov/pubwebapp/external.html?q=(12128026).pn.

User Image joe77w Posted - 10/29/24

$ONCT trying to sell and/or outlicensed, drug seems have value

User Image justiceforb_85 Posted - 10/29/24

$ONCT bit confused by the messaging from the company. They are discontinuing development of ONCT-534 but see value in the therapy?

User Image Bobby_J_Bomb Posted - 10/29/24

$ONCT done building!!! $VSTM Sold 30% Holding 25k long $VTGN Building $AADI Holding for data $SPRB Holding for data

Analyst Ratings
HC Wainwright & Co. Buy Aug 12, 24
HC Wainwright & Co. Buy Jul 16, 24
HC Wainwright & Co. Buy May 31, 24
HC Wainwright & Co. Buy May 13, 24
HC Wainwright & Co. Buy Apr 15, 24
HC Wainwright & Co. Buy Jan 29, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
BREITMEYER JAMES B Chief Executive Offi.. Chief Executive Officer Apr 13 Buy 0.29 150,000 43,500 196,544 04/17/23
Yazji Salim Chief Medical Office.. Chief Medical Officer Apr 12 Buy 0.29 25,000 7,250 164,676 04/14/23
Leavitt Chase C. General Counsel/Secr.. General Counsel/Secretary Apr 12 Buy 0.29 25,000 7,250 106,901 04/14/23
VINCENT RICHARD G Chief Financial Offi.. Chief Financial Officer Apr 13 Buy 0.2987 30,000 8,961 156,859 04/14/23